口咽癌调强放疗中保护管状腺的剂量学可行性初步研究
本研究对17例接受根治性放疗的口咽癌患者勾画管状腺,并重新优化调强放疗计划以保护管状腺同时维持靶区覆盖。重新优化后同侧和对侧管状腺平均剂量分别降低4.9 Gy和7.0 Gy(p < 0.01),同侧管状腺平均剂量≤39 Gy的比例在临床计划与重新优化计划中分别为35%与47%,对侧为70%与100%。
要点
- 重新优化计划使同侧和对侧管状腺平均剂量分别降低4.9 Gy和7.0 Gy(p < 0.01)。
- 同侧管状腺平均剂量≤39 Gy的比例在临床计划与重新优化计划中分别为35%与47%。
- 对侧管状腺平均剂量≤39 Gy的比例在临床计划与重新优化计划中分别为70%与100%。
核心结论
- 本初步研究显示调强放疗保护管状腺在剂量学上是可行的。
- 剂量学约束条件需通过更大规模的研究来确定。
研究设计与样本
- 对17例接受根治性放疗的口咽癌患者勾画管状腺,并重新优化治疗计划以保护管状腺同时维持靶区覆盖。
- 采用配对t检验比较管状腺平均剂量和靶区覆盖。
主要发现
- 同侧和对侧管状腺平均剂量差异分别为4.9 Gy和7.0 Gy(p < 0.01)。
- 同侧管状腺平均剂量≤39 Gy的比例在临床计划与重新优化计划中分别为35%与47%。
- 对侧管状腺平均剂量≤39 Gy的比例在临床计划与重新优化计划中分别为70%与100%。
- 重新优化后同侧管状腺平均剂量≤39 Gy在舌根原发患者中比扁桃体原发患者更常见(86% vs. 20%,p = 0.02)。
局限性
- 本研究的剂量学约束条件需通过更大规模的研究来确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tubarial glands are a new organ at risk for head and neck cancer radiation therapy (RT). We aimed to study the feasibility of sparing them using intensity-modulated radiation therapy (IMRT). METHODS: Tubarial glands were delineated for 17 patients with oropharyngeal carcinoma receiving definitive RT, and treatment plans were re-optimized to spare dose to the tubarial glands while maintaining target coverage. A paired t test was performed to compare the mean dose of tubarial glands and target coverage. RESULTS: The difference in mean doses was 4.9 and 7.0 Gy for the ipsilateral and contralateral tubarial glands, respectively (p < 0.01). The mean dose to tubarial gland was ≤39 Gy in 35% versus 47% (ipsilateral) and 70% versus 100% (contralateral) in clinical and re-optimized plans, respectively. Re-optimized ipsilateral tubarial gland mean ≤39 Gy was achieved more commonly in patients with base of tongue versus tonsil primaries (86% vs. 20%, p = 0.02). CONCLUSION: This pilot study demonstrates the dosimetric feasibility of tubarial gland sparing with IMRT. Dosimetric constraints need to be determined with larger studies.
引用
- Yarlagadda S, McAllister N, Rzepczynski AE, et al. Tubarial gland sparing with intensity modulated radiation therapy for oropharyngeal cancers: A pilot study of dosimetric feasibility. Head Neck. 2024. PMID: 38747190. doi:10.1002/hed.27791
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。